Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic...
Last updated: 2026-04-10 15:31:42 ET
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic...
Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE